NVS · Novartis AG
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVS
this stock
Novartis AG
|
$286.78B | +9.4% | — | — | 0.3% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.8% | +44.7% | 39.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$627.42B | +25.8% | +6.0% | 30.2 | 1.1% |
|
ABBV
AbbVie Inc.
|
$440.83B | +9.2% | +8.6% | 70.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$335.14B | +29.1% | +1.3% | 108.7 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVS | -3.5% | -1.9% | -8.4% | -3.4% | +9.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.9% | -6.3% | -22.2% | -7.3% | -4.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.